NGNE | Neurogene Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	22.96 - 24.83
52 Week Range	14.44 - 74.49
Beta	1.61
Implied Volatility	102.82%
IV Rank	11.87%
Day's Volume	156,310
Average Volume	383,617
Shares Outstanding	20,979,700
Market Cap	481,903,709
Sector	Healthcare
Industry	Biotechnology
IPO Date	2014-03-07

Valuation
Profitability
Growth
Health
P/E Ratio	-5.62
Forward P/E Ratio	N/A
EPS	-4.09
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	91
Country	USA
Website	NGNE

Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.

*Chart delayed

Analyzing fundamentals for NGNE we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see NGNE Fundamentals page.

Watching at NGNE technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on NGNE Technicals page.